PT1622639E - Injecção intravenosa de activadores do plasminogénio não neurotóxico para tratamento do acidente vascular cerebral - Google Patents

Injecção intravenosa de activadores do plasminogénio não neurotóxico para tratamento do acidente vascular cerebral Download PDF

Info

Publication number: PT1622639E
Authority: PT; Portugal
Prior art keywords: dspa; stroke; plasminogen; treatment; tissue
Prior art date: 2003-05-02

Application number

PT47305164T

Other languages

English (en)

Portuguese (pt)

Inventor

Wolf-Dieter Schleuning

Mariola Soehngen

Wolfgang Soehngen

Robert Medcalf

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-02

Filing date

2004-04-30

Publication date

2013-04-01

2004-04-30 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2013-04-01 Publication of PT1622639E publication Critical patent/PT1622639E/pt

Links

208000006011 Stroke Diseases 0.000 title claims description 62
231100000501 nonneurotoxic Toxicity 0.000 title description 20
102000013566 Plasminogen Human genes 0.000 title description 16
108010051456 Plasminogen Proteins 0.000 title description 16
239000012190 activator Substances 0.000 title description 4
238000010253 intravenous injection Methods 0.000 title description 4
238000011282 treatment Methods 0.000 claims description 61
238000002347 injection Methods 0.000 claims description 40
239000007924 injection Substances 0.000 claims description 40
238000001802 infusion Methods 0.000 claims description 30
238000001990 intravenous administration Methods 0.000 claims description 18
230000001225 therapeutic effect Effects 0.000 claims description 11
238000002560 therapeutic procedure Methods 0.000 claims description 7
102100040025 Interferon-induced transmembrane protein 10 Human genes 0.000 claims 1
101710101654 Interferon-induced transmembrane protein 10 Proteins 0.000 claims 1
230000000694 effects Effects 0.000 description 48
102000001938 Plasminogen Activators Human genes 0.000 description 47
108010001014 Plasminogen Activators Proteins 0.000 description 47
229940127126 plasminogen activator Drugs 0.000 description 47
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 37
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 37
229950003499 fibrin Drugs 0.000 description 37
229950006874 kainic acid Drugs 0.000 description 37
108010073385 Fibrin Proteins 0.000 description 36
102000009123 Fibrin Human genes 0.000 description 36
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 36
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 36
210000001519 tissue Anatomy 0.000 description 31
241000699670 Mus sp. Species 0.000 description 27
230000003902 lesion Effects 0.000 description 21
230000004770 neurodegeneration Effects 0.000 description 20
241000700159 Rattus Species 0.000 description 17
210000001320 hippocampus Anatomy 0.000 description 17
241001465754 Metazoa Species 0.000 description 16
210000004556 brain Anatomy 0.000 description 15
206010029350 Neurotoxicity Diseases 0.000 description 14
206010044221 Toxic encephalopathy Diseases 0.000 description 14
231100000228 neurotoxicity Toxicity 0.000 description 14
230000007135 neurotoxicity Effects 0.000 description 14
230000002537 thrombolytic effect Effects 0.000 description 14
108010049003 Fibrinogen Proteins 0.000 description 13
102000008946 Fibrinogen Human genes 0.000 description 13
102000018899 Glutamate Receptors Human genes 0.000 description 13
108010027915 Glutamate Receptors Proteins 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 13
230000001419 dependent effect Effects 0.000 description 13
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 12
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 12
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 12
229940012952 fibrinogen Drugs 0.000 description 12
229930195712 glutamate Natural products 0.000 description 12
238000012360 testing method Methods 0.000 description 12
229960005356 urokinase Drugs 0.000 description 12
108010023197 Streptokinase Proteins 0.000 description 11
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 11
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 11
230000004913 activation Effects 0.000 description 11
230000003492 excitotoxic effect Effects 0.000 description 11
230000035945 sensitivity Effects 0.000 description 11
229960005202 streptokinase Drugs 0.000 description 11
206010008111 Cerebral haemorrhage Diseases 0.000 description 10
108091005804 Peptidases Proteins 0.000 description 10
102000035195 Peptidases Human genes 0.000 description 10
239000004365 Protease Substances 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
238000000034 method Methods 0.000 description 10
231100000063 excitotoxicity Toxicity 0.000 description 9
238000011835 investigation Methods 0.000 description 9
230000035772 mutation Effects 0.000 description 9
230000001537 neural effect Effects 0.000 description 9
230000002797 proteolythic effect Effects 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
229960000103 thrombolytic agent Drugs 0.000 description 8
108010022999 Serine Proteases Proteins 0.000 description 7
102000012479 Serine Proteases Human genes 0.000 description 7
239000003146 anticoagulant agent Substances 0.000 description 7
230000008499 blood brain barrier function Effects 0.000 description 7
210000001218 blood-brain barrier Anatomy 0.000 description 7
230000003197 catalytic effect Effects 0.000 description 7
230000002950 deficient Effects 0.000 description 7
238000010494 dissociation reaction Methods 0.000 description 7
230000005593 dissociations Effects 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000003480 fibrinolytic effect Effects 0.000 description 7
208000020658 intracerebral hemorrhage Diseases 0.000 description 7
210000001577 neostriatum Anatomy 0.000 description 7
230000002887 neurotoxic effect Effects 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
102000010911 Enzyme Precursors Human genes 0.000 description 6
108010062466 Enzyme Precursors Proteins 0.000 description 6
239000000284 extract Substances 0.000 description 6
239000003527 fibrinolytic agent Substances 0.000 description 6
230000006872 improvement Effects 0.000 description 6
210000002569 neuron Anatomy 0.000 description 6
241000288900 Desmodus rotundus Species 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
210000005013 brain tissue Anatomy 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
230000000971 hippocampal effect Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
231100000189 neurotoxic Toxicity 0.000 description 5
238000011002 quantification Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000010186 staining Methods 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
238000011287 therapeutic dose Methods 0.000 description 5
230000000451 tissue damage Effects 0.000 description 5
231100000827 tissue damage Toxicity 0.000 description 5
208000037816 tissue injury Diseases 0.000 description 5
229960000187 tissue plasminogen activator Drugs 0.000 description 5
201000006474 Brain Ischemia Diseases 0.000 description 4
206010008120 Cerebral ischaemia Diseases 0.000 description 4
108090000317 Chymotrypsin Proteins 0.000 description 4
108010088842 Fibrinolysin Proteins 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
206010008118 cerebral infarction Diseases 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000001361 intraarterial administration Methods 0.000 description 4
210000000274 microglia Anatomy 0.000 description 4
239000013642 negative control Substances 0.000 description 4
230000001067 neuroprotector Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
VOROEQBFPPIACJ-UHFFFAOYSA-N 5-Phosphononorvaline Chemical compound OC(=O)C(N)CCCP(O)(O)=O VOROEQBFPPIACJ-UHFFFAOYSA-N 0.000 description 3
208000035404 Autolysis Diseases 0.000 description 3
102000004506 Blood Proteins Human genes 0.000 description 3
108010017384 Blood Proteins Proteins 0.000 description 3
108091005462 Cation channels Proteins 0.000 description 3
206010057248 Cell death Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
229960003318 alteplase Drugs 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000036770 blood supply Effects 0.000 description 3
229960002376 chymotrypsin Drugs 0.000 description 3
102000047823 human PLAT Human genes 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000003364 immunohistochemistry Methods 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229940012957 plasmin Drugs 0.000 description 3
108010051412 reteplase Proteins 0.000 description 3
229960002917 reteplase Drugs 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
108010027612 Batroxobin Proteins 0.000 description 2
RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 2
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
239000012848 Dextrorphan Substances 0.000 description 2
108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229940117892 Glutamate receptor agonist Drugs 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
241000194017 Streptococcus Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
102100026966 Thrombomodulin Human genes 0.000 description 2
108010079274 Thrombomodulin Proteins 0.000 description 2
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 2
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
229940009098 aspartate Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
208000029028 brain injury Diseases 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
210000001638 cerebellum Anatomy 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229960001284 citicoline Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 description 2
229950006878 dextrorphan Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 2
239000000928 excitatory amino acid agonist Substances 0.000 description 2
239000000208 fibrin degradation product Substances 0.000 description 2
230000020764 fibrinolysis Effects 0.000 description 2
239000000834 fixative Substances 0.000 description 2
230000008014 freezing Effects 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000003823 glutamate receptor agonist Substances 0.000 description 2
230000002008 hemorrhagic effect Effects 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000002055 immunohistochemical effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000003447 ipsilateral effect Effects 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
230000007654 ischemic lesion Effects 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
108010087750 lysyl-plasminogen Proteins 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000000178 monomer Substances 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
230000000626 neurodegenerative effect Effects 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
229950010883 phencyclidine Drugs 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
KUUVQVSHGLHAKZ-UHFFFAOYSA-N thionine Chemical compound C=1C=CC=CSC=CC=1 KUUVQVSHGLHAKZ-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
IXNRIBJPEOUGGB-DIKMWTQISA-N (2s)-6-amino-n-[(2r)-2-aminohexanoyl]-n-[(2s)-2-amino-3-(4-hydroxycyclohexyl)propanoyl]-2-(4-nitroanilino)hexanamide Chemical compound C([C@H](N)C(=O)N(C(=O)[C@H](N)CCCC)C(=O)[C@H](CCCCN)NC=1C=CC(=CC=1)[N+]([O-])=O)C1CCC(O)CC1 IXNRIBJPEOUGGB-DIKMWTQISA-N 0.000 description 1
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
-1 APH Chemical compound 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
ICZWAZVKLACMKR-CIUDSAMLSA-N Asp-His-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CN=CN1 ICZWAZVKLACMKR-CIUDSAMLSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
241001631457 Cannula Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
108010027339 H-norleucyl-hexahydrotyrosyl-lysine-4-nitroanilide Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
206010020852 Hypertonia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
238000010826 Nissl staining Methods 0.000 description 1
102220611095 Putative uncharacterized protein PIK3CD-AS1_R15E_mutation Human genes 0.000 description 1
ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
241001635169 Tachia Species 0.000 description 1
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
210000001642 activated microglia Anatomy 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
238000013475 authorization Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229960002210 batroxobin Drugs 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000006567 cellular energy metabolism Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
210000003618 cortical neuron Anatomy 0.000 description 1
238000007727 cost benefit analysis Methods 0.000 description 1
230000000515 cyanogenic effect Effects 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
230000002999 depolarising effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
210000005110 dorsal hippocampus Anatomy 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940124645 emergency medicine Drugs 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003825 glutamate receptor antagonist Substances 0.000 description 1
108010017446 glycyl-prolyl-arginyl-proline Proteins 0.000 description 1
230000003862 health status Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000006724 microglial activation Effects 0.000 description 1
230000002025 microglial effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
230000003961 neuronal insult Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000006959 non-competitive inhibition Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
230000007096 poisonous effect Effects 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
210000001176 projection neuron Anatomy 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
238000012113 quantitative test Methods 0.000 description 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
150000007660 quinolones Chemical class 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
108010073863 saruplase Proteins 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000011664 signaling Effects 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
108010003641 statine renin inhibitory peptide Proteins 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
108010000201 triabin Proteins 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000000280 vitalizing effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Zoology (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

PT47305164T 2003-05-02 2004-04-30 Injecção intravenosa de activadores do plasminogénio não neurotóxico para tratamento do acidente vascular cerebral PT1622639E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EPPCT/EP2003/004608		2003-05-02
PCT/EP2003/004729 WO2004096267A1 (fr)	2003-05-02	2003-05-06	Injection intraveineuse d'activateurs du plasminogene non neurotoxiques pour le traitement de l'accident vasculaire cerebral

Publications (1)

Publication Number	Publication Date
PT1622639E true PT1622639E (pt)	2013-04-01

Family

ID=33395696

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT47305164T PT1622639E (pt)	2003-05-02	2004-04-30	Injecção intravenosa de activadores do plasminogénio não neurotóxico para tratamento do acidente vascular cerebral

Country Status (13)

Country	Link
JP (1)	JP2012077090A (fr)
CN (1)	CN1849133B (fr)
AU (3)	AU2003227721A1 (fr)
CY (1)	CY1114254T1 (fr)
DK (1)	DK1622639T3 (fr)
EA (2)	EA201000501A1 (fr)
ES (1)	ES2401782T3 (fr)
IL (1)	IL171636A (fr)
MY (1)	MY151447A (fr)
PT (1)	PT1622639E (fr)
SI (1)	SI1622639T1 (fr)
WO (1)	WO2004096267A1 (fr)
ZA (2)	ZA200703704B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10153601A1 (de)	2001-11-02	2003-05-22	Paion Gmbh	DSPA zur Behandlung von Schlaganfall
TWI445540B (zh)	2007-04-20	2014-07-21	Ajinomoto Kk	抗低體溫組成物
EP2014296A1 (fr) *	2007-07-10	2009-01-14	PAION Deutschland GmbH	Nouvelles stratégies pour augmenter la reperfusion dans un vaisseau sanguin obturé
AR067345A1 (es) *	2007-07-10	2009-10-07	Paion Deutschland Gmbh	Uso de trombomodulina para la preparacion de un medicamento trombolitico

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE69054B1 (en) *	1988-07-20	1996-08-07	Schering Ag	Vampire bat salivary plasminogen activators
NL8902454A (nl) *	1989-10-03	1991-05-01	Stichting Centraal Lab	Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
DK0530937T3 (da) *	1991-09-05	1999-05-10	Schering Ag	Inhibitor med collagenfremkaldt blodpladeaggregering
DE10153601A1 (de) *	2001-11-02	2003-05-22	Paion Gmbh	DSPA zur Behandlung von Schlaganfall

2003
- 2003-05-06 AU AU2003227721A patent/AU2003227721A1/en not_active Abandoned
- 2003-05-06 WO PCT/EP2003/004729 patent/WO2004096267A1/fr not_active Ceased
2004
- 2004-04-30 DK DK04730516.4T patent/DK1622639T3/da active
- 2004-04-30 EA EA201000501A patent/EA201000501A1/ru unknown
- 2004-04-30 EA EA200501733A patent/EA013837B1/ru not_active IP Right Cessation
- 2004-04-30 ZA ZA200703704A patent/ZA200703704B/xx unknown
- 2004-04-30 AU AU2004233601A patent/AU2004233601B2/en not_active Ceased
- 2004-04-30 CN CN2004800118633A patent/CN1849133B/zh not_active Expired - Fee Related
- 2004-04-30 PT PT47305164T patent/PT1622639E/pt unknown
- 2004-04-30 MY MYPI20041567A patent/MY151447A/en unknown
- 2004-04-30 SI SI200432000T patent/SI1622639T1/sl unknown
- 2004-04-30 ES ES04730516T patent/ES2401782T3/es not_active Expired - Lifetime
- 2004-04-30 ZA ZA200509053A patent/ZA200509053B/en unknown
2005
- 2005-10-27 IL IL171636A patent/IL171636A/en not_active IP Right Cessation
2010
- 2010-02-26 AU AU2010200718A patent/AU2010200718A1/en not_active Abandoned
2012
- 2012-01-10 JP JP2012002501A patent/JP2012077090A/ja active Pending
2013
- 2013-03-26 CY CY20131100248T patent/CY1114254T1/el unknown

Also Published As

Publication number	Publication date
AU2003227721A1 (en)	2004-11-23
AU2004233601B2 (en)	2009-11-26
EA201000501A1 (ru)	2010-10-29
SI1622639T1 (sl)	2013-05-31
ZA200703704B (en)	2008-08-27
AU2010200718A1 (en)	2010-03-18
ES2401782T3 (es)	2013-04-24
CY1114254T1 (el)	2016-08-31
IL171636A (en)	2013-07-31
DK1622639T3 (da)	2013-04-15
WO2004096267A1 (fr)	2004-11-11
EA013837B1 (ru)	2010-08-30
JP2012077090A (ja)	2012-04-19
CN1849133B (zh)	2011-03-30
AU2004233601A1 (en)	2004-11-11
HK1092045A1 (en)	2007-02-02
EA200501733A1 (ru)	2006-06-30
ZA200509053B (en)	2007-11-28
MY151447A (en)	2014-05-30
CN1849133A (zh)	2006-10-18

Publication	Publication Date	Title
US8119597B2 (en)	2012-02-21	Non-neurotoxic plasminogen activating factors for treating of stroke
KR101212631B1 (ko)	2012-12-14	뇌졸중을 치료하기 위한 플라스미노겐 비-신경독성활성인자의 정맥내 주사 방법
JP2006525270A5 (fr)	2012-03-15
JP2012077090A (ja)	2012-04-19	脳梗塞の処置のための非神経毒性プラスミノーゲン活性剤の静脈内注射
US20080057050A1 (en)	2008-03-06	Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20060135425A1 (en)	2006-06-22	Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
MXPA05011761A (en)	2007-04-10	Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
AU2008201735A1 (en)	2008-05-08	Non-neurotoxic plasminogen activating factors for treating stroke
HK1092045B (en)	2013-10-18	Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
HK1057328B (en)	2010-08-13	Non-neurotoxic plasminogen activating factors for treating stroke